EAU 2023 | Exploring the clinical and economic impact of PDD in NMIBC: findings, implications, and future steps

Rakesh Heer, PhD, FRCS(Urol), Newcastle University. Newcastle upon Tyne, London, discusses the next steps following the results of the study on the clinical effectiveness and cost-effectiveness of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumor (TURBT) compared to standard white light (WL)-guided TURBT in patients with non-muscle-invasive bladder cancer (NMIBC) at intermediate or high risk for recurrence. In conclusion, PDD did not show superiority in reducing recurrence rates or cost-effectiveness when compared to WL in NMIBC patients at 3 years of follow-up. The current focus is on raising awareness about the study’s findings and encouraging practitioners to evaluate their own use of PDD. The trial, conducted across 22 UK sites, provided a comprehensive view of the country’s practice and demonstrated that PDD did not offer any value in the studied setting. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.